Top 50 Medical Device Startup Investors in China (September 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Qiming Venture Partners
VC Fund
|
26 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $4.4M–$120M |
|
HSG
VC Fund
|
15 | China, United States, Australia | Series B, Series A, Seed | Artificial Intelligence, Biotechnology, Software | $2M–$226M |
|
Cowin Capital
VC Fund
|
14 | China, Hong Kong, United States | Series A, Series B, Seed | Manufacturing, Health Care, Biotechnology | $1.4M–$51M |
|
BioVenture
VC Fund
|
12 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $4.4M–$73M |
|
Shunwei Capital
VC Fund
|
12 | China, United States, India | Series A, Series B, Series C | Manufacturing, Software, Internet | $1.5M–$105M |
|
Taiyu Investment
VC Fund
|
12 | China | Seed, Series A, Angel | Medical, Health Care, Biotechnology | $434k–$100M |
|
IDG Capital
VC Fund
|
12 | China, United States, India | Series A, Series B, Series C | Software, Internet, E-Commerce | $2.9M–$354M |
|
Lilly Asia Ventures
VC Fund
|
11 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$308M |
|
CD Capital
VC Fund
|
11 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
Addor Capital
VC Fund
|
11 | China, Hong Kong, Singapore | Series A, Series B, Seed | Manufacturing, Semiconductor, Electronics | $1.4k–$47M |
|
BioTrack Capital
VC Fund
|
10 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $14M–$168M |
|
EFung Capital
VC Fund
|
9 | China, United States, India | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $1.4M–$100M |
|
Prox Ventures
VC Fund
|
9 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $2.5M–$28M |
|
Matrix Partners China
VC Fund
|
9 | China, United States, Singapore | Series A, Series B, Seed | Health Care, Software, Biotechnology | $1.6M–$137M |
|
Haibang Capital
VC Fund
|
9 | China | Series A, Series B, Angel | Health Care, Biotechnology, Manufacturing | $425k–$79M |
|
BIOCHING CAPITAL
VC Fund
|
9 | China | Angel, Series A, Seed | Medical, Medical Device, Biotechnology | $433k–$15M |
|
Oriza Seed Capital (Oriza Yuandian)
VC Fund
|
8 | China, United States, Singapore | Series A, Seed, Angel | Manufacturing, Health Care, Medical | $223k–$60M |
|
Legend Capital
VC Fund
|
8 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $1.6M–$200M |
|
Northern Light Venture Capital
VC Fund
|
8 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.3M–$60M |
|
ZhenFund
VC Fund
|
8 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Software, E-Commerce | $425k–$30M |
|
Dalton Venture
VC Fund
|
8 | China, India, Canada | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $512k–$50M |
|
Med-Fine Capital
VC Fund
|
8 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $3M–$60M |
|
SND Ventures Group
VC Fund
|
7 | China | Series A, Series B, Seed | Manufacturing, Semiconductor, Health Care | $1.4M–$28M |
|
Jan Hammer
Angel
|
7 | China, United States, France | Series A, Series B, Seed | Health Care, Medical, Medical Device | $2.5M–$231M |
|
Oriza Holdings
VC Fund
|
6 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $1.5M–$200M |
|
Shenzhen Capital Group
VC Fund
|
6 | China, United States, Japan | Series A, Series B, Series C | Manufacturing, Health Care, Software | $1.5M–$156M |
|
Huagai Capital
VC Fund
|
6 | China, United States, Hong Kong | Series A, Series B, Angel | Health Care, Biotechnology, Medical | $425k–$90M |
|
Haiyuan Capital
VC Fund
|
6 | China | Series A, Seed, Angel | Manufacturing, Medical, Semiconductor | $432k–$15M |
|
Marathon Venture Partners
VC Fund
|
6 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.4M–$142M |
|
Highlight Capital
VC Fund
|
6 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3M–$84M |
|
SZHTI Group
VC Fund
|
6 | China, United States | Series A, Angel | Manufacturing, Electronics, Semiconductor | $425k–$16M |
|
Sunland Fund
VC Fund
|
6 | China | Series A, Series B, Seed | Health Care, Medical, Medical Device | $1.4M–$28M |
|
Share Capital
VC Fund
|
6 | China, United States, Colombia | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $142k–$93M |
|
Huaige Capital
VC Fund
|
5 | China | Series A, Angel, Seed | Medical, Health Care, Biotechnology | $455k–$36M |
|
Frees Fund
VC Fund
|
5 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Health Care, Biotechnology | $447k–$35M |
|
CDH Investments
VC Fund
|
5 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Biotechnology, Health Care | $7.3M–$220M |
|
Tsinghua Innovation Ventures
VC Fund
|
5 | China | Series A, Venture - Series Unknown, Seed | Manufacturing, Medical, Health Care | $832k–$23M |
|
Fortune Venture Capital
VC Fund
|
5 | China, Japan, United States | Series A, Series B, Seed | Manufacturing, Software, Information Technology | $462k–$73M |
|
Apricot Capital
VC Fund
|
5 | China, United States, Hong Kong | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $3M–$58M |
|
Legend Star
VC Fund
|
5 | China, United States, France | Series A, Seed, Angel | Health Care, Medical, Biotechnology | $425k–$52M |
|
HY Capital
VC Fund
|
4 | China, United States | Series A, Seed, Series B | Health Care, Medical, Medical Device | $83k–$28M |
|
Insight Capital
VC Fund
|
4 | China, Thailand, United Kingdom | Series A, Seed, Series B | Health Care, Medical, Medical Device | $2.9M–$65M |
|
Luminous Ventures (former Lightspeed China Partners)
VC Fund
|
4 | China, United States, Singapore | Series A, Series B, Seed | Manufacturing, Internet, Software | $3M–$110M |
|
Volcanics Venture
VC Fund
|
4 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Artificial Intelligence, Biotechnology | $350k–$60M |
|
Tasly Capital
VC Fund
|
4 | China | Series A, Series B, Seed | Medical, Biotechnology, Health Care | $14M–$42M |
|
Qiaojing Capital
VC Fund
|
4 | China | Series A, Series B, Post-IPO Equity | Health Care, Medical, Medical Device | $1.4M–$40M |
|
ASBV
VC Fund
|
4 | China, Australia, Hong Kong | Seed, Series A, Angel | Health Care, Medical, Biotechnology | $425k–$34M |
|
Green Pine Capital Partners
VC Fund
|
4 | China, United States, Canada | Series A, Angel, Series B | Artificial Intelligence, Biotechnology, Software | $425k–$150M |
|
Korea Investment Partners
VC Fund
|
4 | South Korea, United States, China | Series A, Series B, Seed | Biotechnology, Health Care, Information Technology | $973k–$50M |
|
Co-Stone Venture Capital
VC Fund
|
3 | China, United States, Hong Kong | Series B, Series A, Series C | Manufacturing, Semiconductor, Health Care | |
| Access all 1541 investors in China Medical Device startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 1112
- Round size: Series A $4.4M–$50M; Series B $8.5M–$88M; Series C $12M–$120M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fresh fund, raised $8M in 2026
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Guangjing Energy — Guangjing Energy specializes in the R&D and mass production of durable, large-area perovskite solar cell modules. They develops perovskite film printing technology with independent intellectual property rights and realized the preparation of large-area perovskite components.
- Shennapsi Artificial Intelligence Technology — Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterolmonitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
HSG is a leading venture capital and private equity firm investing globally in the technology, healthcare, and consumer sectors.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Software
- Stage:Series B, Series A, Seed
- Geography: China, United States, Australia
Investor stats
- Total investments: 970
- Round size: Seed $2M–$50M; Series A $4.4M–$100M; Series B $12M–$226M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $2.5B in 2024
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Hypershell — An exoskeleton innovator reshaping lifestyles and enabling technology to empower life.
- Suisheng Technology — Suisheng Technology is an innovative company specializing in AI-driven memory services, dedicated to developing intelligent solutions that help individuals and businesses capture, organize, and retrieve important information with greater efficiency and precision.
Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 345
- Round size: Seed $1.4M–$20M; Series A $4.3M–$51M; Series B $2.8M–$50M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- Bytetree — Bytetree is a technology company that focuses on providing the one-stop AI data services for data collection, cleaning, labeling, management, and storage for OEMs and autonomous driving solution providers, covering bicycle intelligence. , vehicle-road coordination, and smart cockpit three scenarios.
- Sunrise — Sunrise is a high-performance GPU developer specializing in GPU research and development.
- Digital China — Digital China is a robotics company focused on developing humanoid interactive robots that can break traditional boundaries and create emotionally resonated partners.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 189
- Round size: Seed $7.9M–$41M; Series A $4.4M–$47M; Series B $7.1M–$73M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $204M in 2016
Portfolio highlights
- SiranBio — SiranBio is a biotechnology that develops innovative siRNA drugs.
- AusperBio — AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Internet
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 574
- Round size: Series A $1.5M–$35M; Series B $8M–$55M; Series C $25M–$105M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- uban — Uban provides an internet office leasing and trading services platform that helps to connect owners, customers and brokers, corporate customers in order to provide office rental and follow-up services, enabling its clients to receive real estate related services through a single portal. The company is based in Beijing, China.
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Darma — DARMA - Digital Healt
Taiyu Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 49
- Round size: Seed $2.8M–$20M; Angel $434k–$100M; Series A $13M–$29M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Immunocan — Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs.
- Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
- Infineon Multiomics — Infineon Multiomics is a biotechnology company that provides research and application of space multiomics technology.
IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Software, Internet, E-Commerce
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 1057
- Round size: Series A $2.9M–$100M; Series B $7.1M–$115M; Series C $15M–$354M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- AIxCrypto — Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as the expansion of its flagship FastPack® diagnostic platform.
- Hypershell — An exoskeleton innovator reshaping lifestyles and enabling technology to empower life.
- Chengjia Apartment — Chengjia Apartment is a rental start-up that provides different product choices for apartments, hotels, and homestays. Chengjia Apartment extends the business scope to weekly rent, monthly rent, and long-term rent. The company creates a high-quality living environment with ingenuity, take care of every guest with hotel-style service, and creates awarm, comfortable, and temperature-friendly home.Chengjia Apartment is jointly established by China Living Hotel Group and IDG Capital. It has laid out nearly 100 properties in first-tier cities nationwide, with more than 10,000 houses and services.It was founded on 2015 and is headquartered in Shanghai, China.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 244
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $30M–$308M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
- Abogen Biosciences — Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 73
- Round size: Seed $1.4M–$15M; Series A $1.5M–$32M; Series B $7.6M–$34M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
- Pipi Bear — Pipi Bear is a creator of living robots and health goods, with a focus on those that improve the lives of the elderly.
- CORE Biomedicine — CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology.
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, Singapore
Investor stats
- Total investments: 357
- Round size: Seed $1.4k–$14M; Series A $1.6M–$44M; Series B $11M–$47M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $241M in 2021
Portfolio highlights
- Ibeki — Ibeki provides tiny photoelectric displacement sensors and servo control systems. eBridge uses the high precision and miniaturization of its precision motion drive technology to provide customers with a more complete technology portfolio, and has successfully transformed its core technology into a number of military and civilian products,particularly in aerospace, medical equipment, and intelligent control.
- Beta Infinite — Beta Infinite approaches data and model technologies in a distinctive and distinctive way.
- Ruimeng Semiconductor — Ruimeng Semiconductor is a provider of intelligent human-machine interface processor chips and solutions.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 94
- Round size: Seed $15M–$168M; Series A $14M–$45M; Series B $15M–$147M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Taiyi Quantum — Taiyi Quantum is dedicated to encouraging innovation in the distribution and implementation of quantum computing technology, as well as developing sophisticated quantum algorithms and delivering tailored computing solutions for businesses and research institutes.
- Convergen — Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases and other conditions driven by protein aggregates
- Zhiyue Space Intelligence — Zhiyue Space Intelligence specializes in robotic brain and brain systems.
Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 84
- Round size: Series A $1.4M–$36M; Series B $14M–$100M; Series C $14M–$74M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Xinyun Life — Xinyun Life Sciences is a high tech medical enterprise focusing on the R&D and industrialization of artificial intelligence vascular intervention devices. The company integrates AI deeply into its hardware development using a unique dual closed- oop system.
- Yuewei Medical — Yuewei Medical is a developer of cardiac surgery interventional medical devices.
- Heluo New Image — Heluo New Image is a cell treatment platform developer that focuses on iPSC directed differentiation, gene editing, large-scale cell product production, and cell therapy technology development.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 82
- Round size: Seed $2.5M–$14M; Series A $3M–$28M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 622
- Round size: Seed $1.6M–$74M; Series A $2.9M–$61M; Series B $10M–$137M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $92M in 2023
Portfolio highlights
- Lexin — LexinFintech Holdings is an online consumer finance platform for educated young adults in China. As one of China's leading financial technology companies, Lexin integrates its e-commerce-driven installment finance platform, Fenqile, with advanced risk management technologies, the Company's Dingsheng online investment platform, and theCompany's Juzi Licai online investment platform for individual investors, to create a comprehensive consumer finance ecosystem. The Company utilizes technologies including big data, cloud computing and artificial intelligence to enable the near-instantaneous matching of user funding requests with offers from the Company's more than 30 funding partners, which include commercial banks, consumer finance companies, and other licensed financial institutions. By serving the credit needs of China's educated young adults, Lexin helps its more than 20 million registered users to enjoy a better quality of life through the use of better credit.
- Camera360 — Camera360 is a professional but easy-to use App for photo editing and selfie retouching. Tag #camera360
- Liepin — Liepin is the largest and most professional high-end talent community-based recruitment site, with its innovative products and unique service model model for create an interactive high-end talent recruitment platform between business, headhunting and workplace. Tens of thousands of professional executive search consultant for businesses and jobseekers set up communication between the bridge and accelerate corporate recruitment process, recommended paying jobs in the workplace, career development planning. 16 job seekers to avoid the risk of privacy protection, millions of high-end elite member libraries, help enterprises development needs.
Zhejiang Haibang Investment Management Co., Ltd. (also referred as "Haibang Capital") is an investment company focusing on venture capital and private equity. It was established in 2011 in Hangzhou. It was founded by Naxin Yao, the CEO of Focused Photonics, Inc (300203), a number of returnee entrepreneurs and experienced investmentprofessionals. In 2011, Haibang Capital launched its first Haibang Fund (formerly called “Haibang Talent Fund”) which was the first venture capital in China helping new returnees to start their own businesses. It is also a fund connect capital and "Thousand Talent Program" in Zhejiang Province. Haibang Capital keeps working on helping enterprises grow rapidly and build leading edge in their industry. In addition to providing capitals, Haibang Capital provides its investee companies with personalized value-added services, helping create both good economic and social benefits.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Series B, Angel
- Geography: China
Investor stats
- Total investments: 50
- Round size: Angel $425k–$2.8M; Series A $1.4M–$15M; Series B $10M–$79M
- Lead/follow: 20% lead, 80% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- MatriQ —
- Hopstem — Hopstem is a Hangzhou-based pharmaceutical company, engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.
- Hongde New Materials — Hongde New Materials produces thermoplastic composite materials with fiber reinforcement. It offers energy storage and auxiliary components for solar and automobile power and steering systems.
BIOCHING CAPITAL is an investment management firm.
Show more...Investment focus
- Industry: Medical, Medical Device, Biotechnology
- Stage:Angel, Series A, Seed
- Geography: China
Investor stats
- Total investments: 20
- Round size: Angel $433k–$15M; Series A $14M–$14M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Lunke Medical — Lunke Medical focuses on the research, development, production, and sales of medical devices, with particular strength and expertise in high-pressure technologies. The company is committed to delivering safe, reliable, and innovative solutions by combining advanced engineering, strict quality control, and continuous technological advancement tomeet the evolving needs of the medical industry.
- Taose Tuantuan — Taose Tuantua is a sex toy company that primarily offers TAOSETT sex toy academy and exquisite sex toy community store services.
- Qinglan Jichuang — Qinglan Jichuang is a domestic high-performance intelligent endoscope innovative enterprise.
Oriza Seed Venture Capital, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. Oriza Seed is a market-oriented investment platform. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of Healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcarefield. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies, including Ascentage Pharma, Innovent Biologics, and SceneRay Corporation.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Medical
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 151
- Round size: Seed $223k–$25M; Angel $425k–$15M; Series A $1.4M–$60M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Youshu Quantum — Youshu Quantum is a deep-tech startup specializing in quantum computing software, middleware, and proprietary algorithms.
- Jitian Xingzhou — Jitian Xingzhou is a commercial aerospace company that provides optical main payloads in batches as one of its primary operations.
- Thortime Technology — Thortime Technology is a hard-tech company specializing in the full-stack development, manufacturing, and delivery of Neutral Beam Injection systems for controllable nuclear fusion devices.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 481
- Round size: Series A $1.6M–$93M; Series B $11M–$107M; Series C $15M–$200M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Huixin Bio — Huixin Bio is a developer of exosome purification products and early cancer detection technology.
- Shunyuan Technology — Shunyuan Technology is a high-tech enterprise specializing in the development of fusion simulators and advanced route design solutions, providing innovative technologies and intelligent systems for complex engineering, transportation, and industrial applications.
Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 360
- Round size: Seed $1.3M–$60M; Series A $2.9M–$40M; Series B $10M–$58M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
- Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, E-Commerce
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 631
- Round size: Seed $443k–$15M; Angel $425k–$5.8M; Series A $1.4M–$30M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — raised $140M in 2022
Portfolio highlights
- Ehang — Ehang is a technology enterprise focused on R&D and production in airplane and aircraft field. With the combination of software and hardware techniques, it self-developed the communication and real-time viewing hardware and a smartphone operation system. Its product, Ghost, is accepted as the first truly smartphone app operated intelligentrobot, which is widely used in geographical information surveying, professional television aerial filming, roadshow displaying, disaster rescuing and delivery, surveillance and monitoring, and even expected to play important role in the future logistics areas.Ehang was founded in 2014 by makers from China, America, and Singapore who are enthusiastic about drone flying. The enterprise’s core members graduated from Tsinghua University, Peking University, and Duke University in America.
- Snowplus — SNOWPLUS is an e-cigarette brand that provides users with e-cigarette products through a combination of online and offline sales models. The products are available in 12 different types of flavors. The products use TrueFeel honeycomb ceramic atomization technology and Aeroflow intake. Technology; In addition to reference to the existing food-gradestandards in China, Xuejia has also passed a number of third-party certifications in terms of safety. The core components such as atomizing core and cigarette holder comply with the highest medical safety standards of the FDA and the European Union.
- Futuring Robot — Futuring Robot is a developer of dual-arm home service robots focusing on C-end home scenarios.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: China, India, Canada
Investor stats
- Total investments: 142
- Round size: Seed $512k–$5M; Series A $2.9M–$17M; Series B $2.8M–$50M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- PowerMicro — PowerMicro focuses on the cutting-edge interdisciplinary field of “stem cells + engineered scaffolds,” specializing in the application of iPSC technology to advance regenerative medicine, tissue engineering, and innovative therapeutic solutions.
- NewPro — NewPro is in the process of increasing production and establishing regulations for lactoferrin raw materials, with the goal of bringing the product to market as quickly as feasible.
- Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 83
- Round size: Seed $8M–$60M; Series A $3M–$40M; Series B $12M–$60M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $73M in 2019
Portfolio highlights
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Tianyikang Biotechnology — Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products.
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
SND Ventures Group is a venture capital and private equity firm specializing in seed investments.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Health Care
- Stage:Series A, Series B, Seed
- Geography: China
Investor stats
- Total investments: 84
- Round size: Series A $1.4M–$21M; Series B $1.4M–$28M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Ruiqi Deep Space — Ruichi Deep Space is an intelligent remote sensing constellation company built on space-based capabilities and driven by AI , aiming to construct a " commercial aerospace" platform.
- Jipai Electromagnetic — Jipai Electromagnetic specializes in the manufacture of automobile components and accessories.
- Sicui Thermal Control — Sicui Thermal Control focuses on the design of next-generation semiconductor and microelectronics thermal management solutions.
Jan Hammer is the partner at Index and the Board observer of Harmonic. Jan attended Oxford University.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States, France
Investor stats
- Total investments: 143
- Round size: Seed $2.5M–$20M; Series A $3M–$35M; Series B $14M–$231M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Transak — Transak offers a simple integration to allow your users to buy more than 100+ cryptocurrencies with credit/debit cards, or bank transfers in more than 120+ countries.
- Yuetong Eye Clinic — Yuetong Eye Clinic is a medical institution that provides myopia surgery for adults and myopia prevention and control for adolescents. It is a medical institution focusing on adult myopia surgery and adolescent myopia prevention and control.
- Xiwei Biotechnology — Xiwei Biotechnology is an ophthalmology implanted medical device developer that specializes in the unique product development of new bio-modified materials for ocular implantable medical devices and regenerative medicine.
Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 217
- Round size: Series A $1.5M–$55M; Series B $10M–$100M; Series C $14M–$200M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- ChipSine — ChipSine is an Integrated Circuit (IC) design company that focuses on the research and development of automotive-grade electronic control chips.
- Empower — Empower is an enterprise platform focused on intelligent laser manufacturing that makes lasers smart.
- Neowise — XinjingZhiyuan is an immune cell therapy company focusing on solid tumors.
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 601
- Round size: Series A $1.5M–$128M; Series B $13M–$141M; Series C $4.4M–$156M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Angel
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 150
- Round size: Angel $425k–$15M; Series A $1.4M–$73M; Series B $3.5M–$90M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- SeaArt — SeaArt AI is an all-in-one AI creativity community for art, videos, audio, and AI chats, where creators collaborate, spark inspiration, and grow together.
- GigaAI — Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space.
- Falcon Technology — Falcon Technology focuses on DSA processor design innovation, developing a dedicated computing technology ecosystem based on the RISC-V architecture to deliver high-performance, energy-efficient processing solutions for next-generation intelligent computing applications.
Goldport Capital is a Shenzhen-based asset management company.
Show more...Investment focus
- Industry: Manufacturing, Medical, Semiconductor
- Stage:Series A, Seed, Angel
- Geography: China
Investor stats
- Total investments: 74
- Round size: Seed $1.4M–$15M; Angel $432k–$14M; Series A $1.4M–$15M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- Anxin Medical — Anxin Medical is a company dedicated to the research, development, production, and sales of innovative medical devices. The company focuses on advancing healthcare technology through continuous innovation, integrating cutting-edge science and engineering to create high-quality, reliable, and efficient medical products.
- Hongxin Biology — Hongxin Bio is an mRNA drug developer, focusing on nucleic acid drug delivery and RNA drug development.
- Huaiye Information — Huaiye Information is a high-tech enterprise specializing in audio and video streaming technologies.
Marathon Venture Partners is an international VC fund that focuses on early and growth stage companies in healthcare and Fintech industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 63
- Round size: Seed $7M–$13M; Series A $1.4M–$29M; Series B $14M–$142M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Fungifuture — Fungifuture is a synthetic biomaterials company specializing in the research and development and production of fungal fiber materials.
- Ruize Health — Ruize Health is a commercial insurance company that focuses on health consumption and commercial insurance.
- Fuxin Technology Innovation — Fuxin Kechuang is a high-tech company that specializes in offering detailed information solutions for the medical and healthcare industries. The business offers creative software solutions and services to a range of healthcare organizations, actively supports the digital transformation of healthcare, and uplifts the medical sector. The company hasgained recognition and has become a partner of big and medium-sized medical institutions and healthcare institutions by relying on its technological research and development power, service capabilities, and ecosystem of medical and health software.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 177
- Round size: Seed $10M–$84M; Series A $3M–$73M; Series B $7.6M–$70M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Genuine Rhythm — Genuine Rhythm is an innovative AI Agent technology developer specializing in bespoke agent creation, advanced algorithm R&D, and rigorous security compliance solutions tailored to diverse enterprise needs.
- PoShell Robotics — PoShell Robotics is a general-purpose home robot, aiming to create a home-friendly and structurally stable robot.
- Xunlu Innovation — Xunlu Innovation is a cutting-edge bicycle manufacturer based in Shenzhen, China, specializing in intelligent electric cargo bikes designed to meet modern urban mobility needs.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!SZHTI Group is a company that provides asset management and financing services.
Show more...Investment focus
- Industry: Manufacturing, Electronics, Semiconductor
- Stage:Series A, Angel
- Geography: China, United States
Investor stats
- Total investments: 134
- Round size: Angel $425k–$1.4M; Series A $780k–$16M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Menovex — Mir Medical Technology is a laser minimally invasive medical treatment enterprise, offering devices, core components, and modules in oral, urological, skin, and vascular fields. With independent research and development capabilities and international marketing, it provides full-cycle laser medical ODM services to domestic and foreign industrypartners.
- Synapath — Synapath focuses on using embodied intelligence and robotics technology to create clever systems for making decisions for multi-domain applications that are intelligent.
- Lingluo Technology — Lingluo Technology is a sleep AI hardware company. It specializes in neurointervention and sleep technology.
Shanlan Capital is a professional fund focused on early and growing health care industry investments with offices in Shanghai and Beijing, focusing on biomedical and medical devices (in vitro diagnostics and gene technology, minimally invasive interventions, implantable devices, minimally invasive High-growth segments such as surgical instrumentsand medical robots, and medical services. It has invested in 15 medical star companies such as Guoke Hengtai, Ricky Surgery, Jingyi Medical, Haipulos, Langhe Medical, etc. The core team of Shanlan Capital is the founder of the medical industry listed company, professional financial and strategic investment. Composition of people, in strategy formulation, talent introduction, technology research and development, market camp..
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China
Investor stats
- Total investments: 35
- Round size: Seed $1.4M–$14M; Series A $1.4M–$16M; Series B $1.5M–$28M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Bochuang Biotechnology — Bochuang Biotechnology is a cutting-edge medical repair product developer that specializes in the controllable electrochemical assembly of biomacromolecules. Bochuang Biotechnology is creating a line of high-end biological tissue functional membranes and derived medical device solutions.
- Insight Technology — Insight Technology is an instrument manufacturer and seller company that specializes in instrument sales, intelligent instrument sales, mechanical equipment research and development, and more.
- Yangshan Medical Technology — Yangshan Medical Technology is a Shanghai-based company specializing in dental surgery robots.
Huaige Capital is a venture capital focusing on healthcare sector.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Angel, Seed
- Geography: China
Investor stats
- Total investments: 23
- Round size: Angel $455k–$14M; Series A $3M–$36M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Heerkang — Heerkang is a medical technology company that provides medical device research and sales, and health consultation services.
- Xianyan Biopharma — Xianyan Biopharma is a company that focuses on core technology innovation and new medication development for oligonucleotides, and it has a top-tier R&D staff.
- Yili Pharmaceutical — Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 229
- Round size: Seed $1.4M–$14M; Angel $447k–$14M; Series A $1.4M–$35M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $144M in 2015
Portfolio highlights
- Chuguang 3D — Chuguang 3D is a optical micro-nano 3D sensor technology platform that focuses on research and development, and manufacturing of micro-nano-level optical three-dimensional sensing and measurement and testing instruments.
- Flysound — Flysound is a hearing technology company focused on making advanced AI-powered hearing aids affordable and accessible. Its products combine AI sound processing, Bluetooth connectivity, app-based personalization, and rechargeable convenience. With a focus on innovation, quality, and user-friendly design, Flysound aims to help people hear moreclearly and stay connected to everyday life.
- Yanming Biology — Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.
CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 316
- Round size: Series A $7.3M–$100M; Series B $14M–$141M; Series C $30M–$220M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- kokoni — kokoni is an innovative, user-friendly 3D printer brand owned by Moxin (Huzhou) Technology Co., LTD
- AusperBio — AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
- Weiling Medical — Wiling Medical offers extensive knowledge of the principles and clinical uses of implantable brain-computer interfaces as well as extensive experience in basic research engineering practise, and clinical care.
Tsinghua Innovation Ventures is an investment management firm.
Show more...Investment focus
- Industry: Manufacturing, Medical, Health Care
- Stage:Series A, Venture - Series Unknown, Seed
- Geography: China
Investor stats
- Total investments: 96
- Round size: Seed $832k–$15M; Series A $1.4M–$23M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Deep Cell — Deep Cell is a Chinese AI driven drug discovery and virtual cell modeling startup. The company integrates artificial intelligence with multi scale molecular physics to construct explainable virtual cell world models, aiming to revolutionize paradigm shifting drug designs and simulate cellular responses to complex diseases.
- FangQing Technology — Fangqing Technology is a company mainly engaged in multiple areas of the communications equipment and software industry. Its core business activities include software development and sales, software outsourcing services, information system integration services, and computer system services.
- Starlink Innovation — Starlink Innovation makes satellite communication terminals, space-ground communication hardware and software, and satellite applications.
Fortune Capital, established in April, 2000, is one of the earliest market-oriented venture capital firms in China. For the past 14 years, Fortune Capital focus its investments on leading companies in four key sectors: TMT (Media oriented), Consumer Goods/Services, Modern Agriculture and Clean Tech.Fortune Capital is ranked among thehighest performing VC/PE firms in China and selected as "Vice President of Venture Capital Committee of IAC," "Vice President of Shenzhen VC Association," "Vice President of Shenzhen Chamber of International Investment & Funding," etc.In addition to providing capitals, Fortune Capital provides its investee companies with personalized value-added services.
Show more...Investment focus
- Industry: Manufacturing, Software, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, Japan, United States
Investor stats
- Total investments: 297
- Round size: Seed $462k–$73M; Series A $1.5M–$70M; Series B $3M–$57M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $860M in 2021
Portfolio highlights
- Xinjie Energy — Xinjie Energy focuses on the research, development, and production of lithium metal solid-state batteries. These batteries aim to offer energy density and improved safety compared to traditional lithium-ion batteries. The company works on advancing battery technology, with potential applications in electric vehicles and energy storage. It isinvolved in advancing solid-state battery technology and expanding its presence in the battery industry.
- Strongest Laser — Strongest Laser is a high-power fiber laser equipment developer.
- NeueHCT — Horizon Continental Technology is a joint venture between Continental Group and Horizon Robotics
Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics.Founded in 2015, Apricot Capital consists of more than 20 professionals and consultants with experience in thehealthcare industry. Its professional background includes life sciences, medicine, finance and law.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 46
- Round size: Seed $10M–$41M; Series A $3M–$54M; Series B $14M–$58M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fresh fund, raised $41M in 2025
Portfolio highlights
- iRegene — iRegene researches and develops pharmaceutical therapy for neurodegenerative and rare diseases.
- Vibrant — Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects tocontinuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization.It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China.
- Microtide Biotechnology — Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine.
Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.Legend Star is the independent early-stage investment arm of LegendHoldings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, France
Investor stats
- Total investments: 161
- Round size: Seed $1.5M–$19M; Angel $425k–$49M; Series A $1.5M–$52M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — raised $127M in 2018
Portfolio highlights
- CellWall — Cellwall is a desktop robot developer focused on the research, development, upgrade, and marketing of its initial product, CyboPal ONE.
- Yuanhao Power — The primary focus of Yuanhao Power, an AI native technology developer, is the creation of fifth-generation multimodal 4D world model base models. It creates a cohesive model system that encompasses dynamic environment reconstruction, generation, simulation, and intelligent agent training, and it encourages its use in applications like autonomousdriving, medical procedures, games and movies, and embodied intelligence. For the era of physical AI, it is dedicated to developing a universal world model base.
- Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!HY Capital is a healthcare industry-focused investment firm that engages in early-stage investments, growth-stage investments.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Seed, Series B
- Geography: China, United States
Investor stats
- Total investments: 21
- Round size: Seed $83k–$14M; Series A $199k–$16M; Series B $14M–$28M
- Lead/follow: 52% lead, 48% follow
Portfolio highlights
- Only Sanbio — Only Sanbio is a synthetic biotechnology company integrating R&D, production, and sales. Itsmed vision is to focus on the field of great health and great beauty, based on synthetic biology technology
- Kang Ruijian — Kang Ruijian is a developer of thermosensitive modified chitin hydrogel technology.
- Linyan Medical — Linyan Medical is a high-tech company focusing on the combination of man and machine in metaverse medical surgery.
Insight Capital is a venture capital firm focused on early-stage investment.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Seed, Series B
- Geography: China, Thailand, United Kingdom
Investor stats
- Total investments: 27
- Round size: Seed $14M–$15M; Series A $2.9M–$14M; Series B $15M–$65M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — raised $72M in 2018
Portfolio highlights
- Sieran Medical — Sieran Medical is a medical device company that provides precise and intelligent minimally invasive surgical treatment solutions for ophthalmology.
- Rigato Medical Technology — Rigato Medical Technology focuses on the R&D and production of medical devices and supplies.
- Hangzhou Dasheng Technology — Hangzhou Dasheng is a high-tech enterprise specializing in the research and development of medical surgical robot systems, dedicated to advancing precision medicine through innovative technologies, integrating artificial intelligence, robotics, and minimally invasive surgical solutions to improve clinical outcomes, enhance surgeon capabilities, andprovide safer, more efficient healthcare services worldwide.
Lightspeed China Partners was founded in 2011 as an independent venture capital group and began operating as Luminous Ventures in November 2025. Luminous Ventures is a leading venture capital firm serving entrepreneurs as a lead investor in early stage and emerging growth companies. It has offices in Shanghai,Beijing and Hong Kong.
Show more...Investment focus
- Industry: Manufacturing, Internet, Software
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 178
- Round size: Seed $4M–$28M; Series A $3M–$86M; Series B $10M–$110M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely actively investing — fresh fund, raised $460M in 2026
Portfolio highlights
- Aerofugia — Aerofugia is a technology company with low-altitude travel and vehicle-mounted flight as its core, and a practitioner of the new general aviation strategy under Geely Technology Group.
- Differential Robotics — Differential Robotics is a robotics company providing research, design, and development of aerial robots and intelligent autonomous drones.
- Extreme shell technology — Extreme shell technology helps in creation and development of exoskeleton equipment for consumers. It uses data to drive exoskeleton innovation.
Volcanics Venture was founded in May 2016. They identify, invest in, and serve the most promising companies and outstanding entrepreneurs in Internet Innovation, Intelligent Technology and Healthcare industry. Managing Partners Suyang Zhang, Yeshun Dong and Ying Wu have been working closely for years as first-class USD/RMB fund managers.They have more than 60 years of aggregated VC investment and corporate management experience, as well as in-depth understanding of three focused fields. Volcanics Venture brings a powerful combination of global perspective and local experience to investment management, striving to provide sustainable value-added service to their portfolio companies and bring superior return to their limited partners.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 105
- Round size: Seed $350k–$17M; Series A $1.4M–$22M; Series B $6.7M–$60M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $73M in 2018
Portfolio highlights
- Unisic — Unisic designs and manufactures silicon carbide core power components. Unisic develops sets of products based on silicon carbide and has applied silicon carbide power modules to aviation, new energy power generation, high-end medical care, oil exploration, lighting, new energy vehicles, data centers, and other important fields.
- EVAS Intelligence — EVAS Intelligence is an autonomous driving chip startup. The company was founded by Liu Hui.
- Fengtai Technology — Focusing on industrial information security, Fujian and Taiwan technology mainly provides professional, standard chemical control safety consulting and evaluation services to ensure information security of key industrial information infrastructure and improve security protection solutions. It mainly serves the government, industry customers, designinstitutes, research institutes, institutes, integrators and hardware and software manufacturers. Through visual, process and customized tools and methods, it helps users to carry out effective risk management and reliable operational support. .
Tasly Capital is an investment arm of Tasly, a Chinese pharmaceutical company.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Series A, Series B, Seed
- Geography: China
Investor stats
- Total investments: 17
- Round size: Series A $14M–$28M; Series B $15M–$42M
- Lead/follow: 53% lead, 47% follow
Portfolio highlights
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Bite Micro — Better Micro Medical is a medical device company that is characterized by intervention and non-implantation, and offers doctors with comprehensive solutions in the field of peripheral vascular and structural heart disease.
- Hopstem — Hopstem is a Hangzhou-based pharmaceutical company, engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.
Qiaojing Capital is an investment firm that invests in the medical, consumer & supply chain financial management industries. Qiao Jing Capital's core operation team has experience in senior management positions in well-known asset management companies at home and abroad. The company's operations fully follow the leading models athome and abroad, and pursue strict risk management and efficient incentive mechanisms.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series B, Post-IPO Equity
- Geography: China
Investor stats
- Total investments: 20
- Round size: Series A $1.4M–$40M; Series B $10M–$15M; Post-IPO Equity $1.5M–$38M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Hicicare — Hicicare is a medical technology company that specializes in the development of pan-vascular interventional medical devices.
- Yisheng Microna — Yisheng Microna is an ultrasonic transducer designer and developer, focusing on providing minimally invasive interventional ultrasonography catheters and transducers.
- Elite Technology — Elite Technology is a company that specializes in the development of chromatographic techniques, workstations, and high-performance liquid chromatography equipment for analysis, preparation, and industrial production.
ASBV focuses on early and mid-term venture capital investments.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China, Australia, Hong Kong
Investor stats
- Total investments: 28
- Round size: Seed $3M–$14M; Angel $425k–$425k; Series A $1.4M–$34M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Kaiyue Life — Kaiyue Life focuses on small molecule medication research & development for the treatment of human Ras mutant solid tumours.
- Boundary Intelligent Control — Boundary Intelligent is specialized in creating airborne systems, such as flight control systems, that satisfy the needs of civil aircraft, as well as enhancing the ecology of the civil aviation industry and constructing aircraft perception, navigation, decision-making, and planning capabilities.
- Longyue Mechanical and Electrical Technology — Longyue Mechanical and Electrical Technology engaged in technologies, strengthened linkages, and provided commercial aircraft services.
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Software
- Stage:Series A, Angel, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 228
- Round size: Angel $425k–$2.9M; Series A $1.4M–$94M; Series B $3M–$150M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely actively investing — fresh fund, raised $42M in 2025
Portfolio highlights
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- IO-AI Tech — IO-AI Tech develops specialized data infrastructure to connect physical robots, AI models, and real-world training environments. The company's core value proposition relies on its end-to-end hardware and software products—such as teleoperation tools and motion capture units—which allow developer teams to capture, visualize, and managehigh-precision multimodal data. By automating complex data pipelines and annotations, the business model scales the collection of high-quality training assets essential for deploying frontier physical intelligence.
- Sungen Biomedical — Sungen Biomedical is an innovative antibody drug R&D enterprise. It has established international standard technology platforms and original biological macromolecular R&D pipelines. Their focus includes therapeutic drugs for cardiovascular and cerebrovascular diseases, tumors, and more.
Korea Investment Partners (KIP) is a leading venture capital & private equity firm that has over 30 years of experience in providing venture capital to bold and innovative entrepreneurs who want to change the world. Korea Investment Partners invests in leading pioneers like Kakao(KOSDAQ:035720), Naver(KRX:035420), YGEntertainment(KOSDAQ:122870), Bodyfriend, Osstem Implant(KOSDAQ:048260), Doubleu Games(KOSDAQ:192080) and Didi Chuxing. KIP manages over 20 venture and private equity funds with US$1.8 billion in total assets under management. The company operates globally from its Seoul headquarters office with other locations in Shanghai, Beijing, and Sunnyvale.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Information Technology
- Stage:Series A, Series B, Seed
- Geography: South Korea, United States, China
Investor stats
- Total investments: 520
- Round size: Seed $973k–$10M; Series A $2.2M–$19M; Series B $4.7M–$50M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely still investing — raised $60M in 2023
Portfolio highlights
- Zamface — Zamface is an app that makes beauty video.
- Wakebunny — Wakebunny is a company that specializes in IP-based commerce, leveraging intellectual property to create, market, and monetize unique products and experiences. By focusing on the strategic use of copyrights, trademarks, and brand assets, Wakebunny transforms original ideas, characters, and stories into commercially viable offerings across variousplatforms such as e-commerce, digital media, merchandising, and licensing.
- Inovio Pharmaceuticals — INOVIO is advancing novel immunotherapy technologies to reshape the future of treating and preventing infectious diseases and cancer.
Co-Stone Capital is a leading China based private equity firm headquartered in Shenzhen. Founded more than 16 years ago, Co-Stone is one of China's earliest private equity institutions. Co-Stone Capital focuses primarily on China domestic growth stage and Pre-IPO opportunities, basing investment decisions on a deep understanding of the Chineseeconomy and company specific growth patterns. We put heavy emphasis on stable growth in key industries, including TMT, healthcare, consumer products & services and advanced manufacturing. Co-Stone Capital approaches the capital markets with broad vision but detailed focus, maintaining an emphasis on value-adding services. We have invested in over 100 companies, the majority of which were lead investments and have successfully exited from 40 companies through IPO, M&A or reverse mergers. Our exit rates and ROI are far in excess of industry averages. Co-Stone Capital has assets under management in excess of 40 billion RMB, across funds covering private equity, venture capital, PIPE, M&A and fixed income. Co-Stone has a diverse capital base, with LPs ranging across large insurance groups, government guided funds, funds of funds, large corporations, entrepreneurs and high net worth individuals. Co-Stone Capital has received numerous accolades from Forbes, Zero2IPO,ChinaVenture and other industry publications which consistently rank us in the top 10. Co-Stone Capital is headquartered in Shenzhen, with offices in Beijing,Shanghai and Hefei.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Health Care
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 140
- Lead/follow: no public data
Portfolio highlights
- PaXini Tech — All Scenario Application—Haptic Digitization and Tactile Technology
- Ganwei Technology — Wuhan Ganwei Technology is a manufacturer of gas instruments and meters. Its main products include short optical path gas pools, online ultraviolet gas analyzers, gas sensors, oil and gas infrared spectroscopy logging tools, and high-precision automatic gas distribution instruments, etc., which are mainly used in environmental protection,Petrochemical and other fields.
- Changzhou Fuxing Mechanical and Electrical Co. — Changzhou Fuxing Mechanical and Electrical Co. manufactures servo, brushless DC, and hybrid stepper motors.
Medical Device Investor funding in China at a glance
Stats across 1.3k deals from 1.5k investors.
Access all 1541 investors in China Medical Device startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical Device Investors in China investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 1541 investors investing in China Medical Device startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!